Developing and validating a clinical risk score to predict losses in the PISCIS cohort of people with HIV

Jorge Palacio-Vieira1,2,3, Yesika Díaz1,2,3, Sergio Moreno-Fornés1,2,3

  • 1Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Dept Salut, Generalitat de Catalunya, Badalona, Spain.

Insights

A new risk score can identify people living with HIV (PLWH) at high risk of being lost to follow-up (LTFU) from care. This tool aids in preventing worse health outcomes for PLWH.

Area of Science:

  • Public Health
  • Epidemiology
  • HIV Medicine

Background:

  • Loss to follow-up (LTFU) from HIV care increases health risks for people living with HIV (PLWH).
  • Predicting LTFU is crucial for maintaining patient health and optimizing HIV care management.
  • Developing targeted interventions requires accurate identification of at-risk individuals.

Purpose of the Study:

  • To develop and validate a predictive risk score for LTFU among PLWH in Catalonia and the Balearic Islands.
  • To identify key factors associated with LTFU in this population.
  • To provide a tool for early intervention and improved patient retention in HIV care.

Main Methods:

  • A cohort of 6661 people living with HIV (PLWH) was analyzed.
  • Logistic regression models identified independent predictors of LTFU (defined as no contact with HIV care for ≥12 months).
  • A 10-fold cross-validation was used to assess model performance and calculate the Area Under the ROC Curve (AUC).

Main Results:

  • Key predictors of LTFU included younger age (<34 years), not being born in Spain, being a man who injects drugs, detectable viral load, and diagnosis within the last 2.5 years.
  • The risk score's validation yielded a mean AUC of 0.69.
  • The score identified 28.8% of PLWH at medium risk and 3.4% at high risk of LTFU.

Conclusions:

  • The developed risk score can effectively predict LTFU in people living with HIV.
  • These findings support the implementation of targeted strategies to prevent LTFU and improve engagement in HIV care.
  • Proactive identification of at-risk individuals is essential for better health outcomes in PLWH.
Abstract

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
627
Relative Risk01:12

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
2.5K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
863
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
756